成果報告書詳細
管理番号20120000001188
タイトル*平成23年度中間年報 「がん超早期診断・治療機器の総合研究開発/超早期高精度診断システムの研究開発/画像診断システムの研究開発/がんの性状をとらえる分子プローブ等の研究開発」
公開日2012/12/19
報告書年度2011-2011
委託先名日本メジフィジックス株式会社
プロジェクト番号P10003
部署名バイオテクノロジー・医療技術部
和文要約和文要約等以下本編抜粋:
1. 研究開発の内容及び成果等
本研究開発プロジェクトの目的は、PET を中心とし他の画像診断機器(SPECT、MRI)
と組み合わせたマルチモダリティイメージングの手法により、がん分子標的治療薬の標的とする分子の発現・活性およびがんの性状を高効率的・多面的に捉え、効果的な治療法の決定に寄与することにある。
英文要約Title: The Advanced Research and Development Project on Diagnosis and Treatment for Early Stage of Cancer. Research and Development Project on High-speck Diagnostic Equipment for Medical Imaging. Research and Development Project on Medical Imaging System. Research and Development Project on Molecular Imaging Probes for Cancer Characterization. Molecular Imaging Probes for Cancer Characterization (FY2010-2012) FY2011 Annual Report
The goal of this R&D project is to develop the multi-modalities imaging methods, combining Positron Emission Tomography (PET) and other imaging devices such as MRI, for the purpose of optimizing the molecular-targeted cancer therapeutics in the personalized clinical settings. In collaboration with Kyoto University, we have decided to develop new PET imaging probes for (1) pancreatic, (2) lung, (3) breast and (4) prostate cancers. Molecular designs of these PET imaging probes would be based on pathophysiological properties and treatment strategies of each tumor. Nihon Medi-Physics (NMP) is in charge of preclinical safety evaluations of the new PET imaging probes to be developed by Kyoto University. This annual report briefly summarizes the R&D activities made by NMP for this project in fiscal year 2011. In FY2011, NMP conducted preliminary safety studies of a new pancreatic cancer imaging probe developed by Kyoto Univ. Single dose toxicity studies using normal mice were performed by AAALAC-certified CRO. Test substances were administrated intravenously to male and female mice (n=10 each). General conditions and body weights of the test animals were observed for two weeks after the administration and compared with control group. After two weeks observation, the test animals were sacrificed and major organs were inspected visually. The initial dose of the test substances was 3μg/kg. Since no particular signs of toxicity caused by the test substances were observed, 30μg/kg was selected as the second dose of this study. As a result, no adverse events caused by the test substances were confirmed following the intravenous injections of the test substances at the doses of 3 and 30μg/kg. This means that there is x10,000 safety margin compared to the putative clinical dose (3ng/kg). Preliminary market research for the new PET imaging probes in the area of pancreatic and lung cancers were also conducted. Clinical unmet needs in these tumors as well as recent developments of molecular targeted therapeutics were reviewed from many professional congresses such as American Society of Clinical Oncology (June 2011 in Chicago), Society of Nuclear Medicine (June 2011 in San Antonio), World Molecular Imaging Congress (September 2011 in San Diego). It is concluded that the understandings on molecular mechanisms of treatment-resistance such as cancer stem cells and hypoxia are critical for designing and developing new PET imaging agents.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る